Lung Biotechnology PBC
Develops 3D bioprinting and perfusion technologies for lung regeneration and transplantation, aiming to address the severe shortage of transplantable organs.
- CEO / Founder
- Martine Rothblatt
- Team Size
- 51-200
- Stage
- Active
- Total Funding
- Undisclosed
- Latest Round
- Venture Round
- Key Investors
- United Therapeutics
Technology & Products
Key Products
Ex vivo lung perfusion (EVLP) services; 3D bioprinting platforms for solid-organ scaffolds; Lung regeneration technologies
Technological Advantage
Proprietary EVLP technology preserves and stabilizes donor lungs; collaboration with 3D Systems for bioprinting scaffolds enables full-size, vascularized organ production.
Patent position
Lung Biotechnology PBC’s focus shifted toward equipment, which rose from 40% to 63% of patent families, while applications fell from 80% to 53%. AMPulse analysis
- Filing momentum
- 23 families filed 2022–2024, 24 in 2019–2021
- Process mix, 2019–2021 → 2022–2024
- Vat photopolymerization 100% → 92%
- Focus, 2019–2021 → 2022–2024
- Equipment 40% → 63%Applications 80% → 53%Materials 35% → 37%
- Filed in
- US 38%WO 30%EP 30%CN 2%
56 AM patent families in total. Recent years are still being published, so read a filing change against the same-office figure.
Differentiation
Value Proposition
Increases the supply of transplantable lungs through ex vivo lung perfusion (EVLP) and 3D bioprinting, potentially reducing wait times and improving patient outcomes.
How They Differentiate
Focuses specifically on lung regeneration using combined perfusion and 3D bioprinting, unlike competitors that may specialize in artificial lungs or broader organ preservation.
Market & Competition
Target Customers
Hospitals, transplant centers, patients with end-stage lung diseases (e.g., pulmonary arterial hypertension)
Industry Verticals
Medical; Biotechnology; Healthcare
Competitors
Miromatrix; XVIVO Perfusion; ALung Technologies Inc.
Growth & Milestones
Growth Metrics
Revenue reported at $16.5M; 51-200 employees; 14 clinical trials
Major Milestones
Formed in 2014 as a subsidiary of United Therapeutics; Collaboration with 3D Systems for 3D bioprinting organ scaffolds; EVLP service enabled 500+ lung transplants since 2014
Notable Customers
Mayo Clinic; XVIVO Perfusion
AM patents
AM-relevant patents linked to this company.
- Patents
- 57
- Granted
- 9
- Families
- 56
Leading domains: process (57), application (33), equipment (22)
Filings by year: 2026: 1 · 2025: 3 · 2024: 1 · 2023: 8 · 2022: 14 · 2021: 22
- INTERPENETRATING POLYMER NETWORKS FOR USE IN SUTURABLE AND FLEXIBLE MATERIALS2024025937 · WO
- POST-PROCESSING OF BIOLOGICAL SCAFFOLDS04683684 · EP
- HIGH RESOLUTION PRINTING SYSTEM AND A METHOD OF ALIGNING PIXELATED TILES20240408826 · US
- MATERIAL AND METHOD FOR PRODUCING CELL RECEIVING SCAFFOLD20260109952 · US
- TRANSWELL FOR CELL CULTURE, METHOD OF MANUFACTURING WITH SYNTHETIC BIOINK AND IN VITRO TISSUE MODELS2024025983 · WO